CDK4/6 inhibitors in breast cancer therapy: Current practice and future opportunities

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Dysregulation of cyclin-dependent kinase (CDK) pathways is implicated in luminal breast cancer, presenting a therapeutic target.
• Early pan-CDK inhibitors exhibited significant toxicities, limiting their clinical utility.
• Recent advancements have led to the development of specific, well-tolerated CDK4/6 inhibitors.

Purpose of the Study:

• To review the therapeutic potential of specific CDK4/6 inhibitors in estrogen receptor-positive breast cancer.
• To discuss the clinical efficacy and safety profiles of approved CDK4/6 inhibitors.
• To explore emerging research and combination strategies involving CDK4/6 inhibitors.

Main Methods:

• Review of clinical trial data for CDK4/6 inhibitors in breast cancer.
• Analysis of drug approval information from regulatory agencies.
• Examination of mechanistic insights into CDK4/6 inhibition.

Main Results:

• Palbociclib, ribociclib, and abemaciclib are FDA-approved CDK4/6 inhibitors for advanced hormone receptor-positive breast cancer.
• These agents, used with endocrine therapy, demonstrated progression-free survival benefits in Phase III trials.
• Common grade 3 side effects include neutropenia, fatigue, nausea, and diarrhea.

Conclusions:

• Specific CDK4/6 inhibitors represent a significant therapeutic advancement for hormone receptor-positive breast cancer.
• Estrogen receptor positivity is the primary predictive biomarker identified to date.
• Ongoing research is investigating combinations of CDK4/6 inhibitors with other therapeutic modalities.